140 related articles for article (PubMed ID: 17474470)
1. [New horizon of chronic myelogenous leukemia].
Tauchi T; Ohyashiki K
Nihon Rinsho; 2007 Jan; 65 Suppl 1():617-21. PubMed ID: 17474470
[No Abstract] [Full Text] [Related]
2. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
[No Abstract] [Full Text] [Related]
3. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
Kroll T; Ames MB; Pruett JA; Fenske TS
Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520
[No Abstract] [Full Text] [Related]
4. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
5. New leukemia drug shows promise against Gleevec resistance.
Ashraf H
Drug Discov Today; 2005 Apr; 10(7):453-4. PubMed ID: 15809187
[No Abstract] [Full Text] [Related]
6. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Gruber FX; Ernst T; Porkka K; Engh RA; Mikkola I; Maier J; Lange T; Hochhaus A
Leukemia; 2012 Jan; 26(1):172-7. PubMed ID: 21818112
[No Abstract] [Full Text] [Related]
7. [Roles of the 2nd generation TKIs for CML].
Matsumura I
Rinsho Ketsueki; 2011 Oct; 52(10):1610-8. PubMed ID: 21971238
[No Abstract] [Full Text] [Related]
8. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
[No Abstract] [Full Text] [Related]
9. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
Fujii Y; Amano M; Seriu T
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
[No Abstract] [Full Text] [Related]
10. Tyrosine kinase inhibitors: the next generation.
Fricker J
Lancet Oncol; 2006 Aug; 7(8):621. PubMed ID: 16900596
[No Abstract] [Full Text] [Related]
11. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Breccia M
Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
[No Abstract] [Full Text] [Related]
12. Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
Gentile M; Guido M; Lucia E; Vigna E; Mazzone C; Recchia AG; Morabito F
Leuk Lymphoma; 2014 Mar; 55(3):709-10. PubMed ID: 23741978
[No Abstract] [Full Text] [Related]
13. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Kantarjian H
Clin Adv Hematol Oncol; 2008 Nov; 6(11):797-9. PubMed ID: 19194361
[No Abstract] [Full Text] [Related]
14. Two new agents effective in Gleevec-resistant CML.
Cancer Biol Ther; 2004 Dec; 3(12):1198-9. PubMed ID: 15864854
[No Abstract] [Full Text] [Related]
15. [Treatment for de novo chronic myeloid leukemia in chronic phase].
Hirase C; Matsumura I
Nihon Rinsho; 2012 Apr; 70 Suppl 2():298-303. PubMed ID: 23133971
[No Abstract] [Full Text] [Related]
16. T315I, more or less, predicts for major molecular response: the devil is in the details!
Mauro MJ
Haematologica; 2013 May; 98(5):665-6. PubMed ID: 23633541
[No Abstract] [Full Text] [Related]
17. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Valent JN; Schiffer CA
Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
[No Abstract] [Full Text] [Related]
18. Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
Sanchez-Guijo FM; Lopez-Jimenez J; Gonzalez T; Santamaría C; González M; Del Cañizo MC
Leuk Res; 2009 Jun; 33(6):e20-2. PubMed ID: 19038446
[No Abstract] [Full Text] [Related]
19. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Yamaguchi M; Munemoto S; Kasada A; Murata R; Ueda M
Leuk Res; 2010 Sep; 34(9):e237-9. PubMed ID: 20371117
[No Abstract] [Full Text] [Related]
20. Glivec and beyond.
Eur J Cancer; 2006 Aug; 42(12):1695. PubMed ID: 16998957
[No Abstract] [Full Text] [Related]
[Next] [New Search]
